Acepodia Presents Preclinical Data on its gamma delta T cell Therapy Candidate ACE1831 at 2022 AACR Meeting

Acepodia Announces Expansion of Board of Directors and Scientific Advisory Board

GlobeNewswire

Acepodia Raises $109 Million Series C Financing to Advance Development of First-in-Class Antibody Cell Effector Therapies

GlobeNewswire

Acepodia Strengthens Board of Directors and Scientific Advisory Board with Key Appointments

GlobeNewswire

Natural Killer Cell Therapy Well Tolerated in Solid Tumors

GeneTherapyLive

Developing Cell Therapies for Solid Tumors and Hematologic Malignancies

GeneTherapyLive

ESMO shifts the HER2 antibody landscape

BioCentury

Acepodia Presents Positive Interim Phase 1 Feasibility Data for Antibody Cell Effector Therapy, ACE1702, in Advanced HER2-Positive Tumors

GlobeNewswire

Creating Off-the-Shelf Cell Therapies for Cancer

Genetic Engineering & Biotechnology News (GEN)

Acepodia Publishes Preclinical Data on Novel Off-the-Shelf Natural Killer Cell Therapy, ACE1702, for HER2-Expressing Solid Tumors Using Antibody-Cell Conjugation Technology in the Journal Cancers

GlobeNewswire

A Novel off-the-Shelf Trastuzumab-Armed NK Cell Therapy (ACE1702) Using Antibody-Cell-Conjugation Technology

Cancers 2021, 13(11), 2724
Hao-Kang Li, Ching-Wen Hsiao, Sen-Han Yang, Hsiu-Ping Yang, Tai-Sheng Wu, Chia-Yun Lee, Yan-Liang Lin, Janet Pan, Zih-Fei Cheng, Yan-Da Lai, Shih-Chia Hsiao and Sai-Wen Tang

Acepodia Presents Data on its Allogeneic Natural Killer-Like Gamma-Delta T Cell Therapy, ACE1831, in Development for Hematological Cancers

GlobeNewswire